Mepolizumab as opposed to placebo for asthma | Cochrane

Asthma is an inflammatory lung condition characterised by the narrowing of the airways, breathlessness, a tight chest and reduced quality of life. By the year 2025, there may be up to 400 million people with asthma worldwide. Mepolizumab is one treatment that may help to reduce the symptoms.